What is Interpace Biosciences?
Interpace Biosciences operates as a pivotal entity in the therapeutic value chain, specializing in molecular diagnostic tests and bioinformatics. The company provides critical insights for cancer risk assessment, bridging the gap between early diagnosis and targeted therapeutic intervention. With a robust suite of commercialized tests—including PancraGEN, ThyGeNEXT, and RespriDX—Interpace leverages next-generation sequencing and microRNA expression profiling to assist clinicians in complex decision-making processes. Their focus on high-stakes oncology diagnostics, such as pancreatic and thyroid cancer management, establishes them as a key player in the precision medicine sector, where clinical evidence and payer reimbursement remain the primary drivers of long-term commercial viability.
How much funding has Interpace Biosciences raised?
Interpace Biosciences has raised a total of $3.6M across 1 funding round:
Stock Offering
$3.6M
Stock Issuance/Offering (2017): $3.6M, investors not publicly disclosed
Key Investors in Interpace Biosciences
Undisclosed Investor
An institutional participant providing capital to support the scaling of molecular diagnostic capabilities and clinical research initiatives.
What's next for Interpace Biosciences?
With the recent influx of capital, Interpace Biosciences is poised to scale its clinical evaluation programs and further validate its pipeline, including the BarreGEN assay. The strategic roadmap likely involves deepening the clinical evidence base to secure broader insurance coverage and enhancing the technological infrastructure supporting their bioinformatics services. As the firm transitions into a more mature phase of enterprise-level operations, the focus will shift toward optimizing the commercial adoption of its existing test menu while simultaneously exploring new diagnostic frontiers. This growth trajectory suggests a sustained effort to integrate advanced molecular insights into standard clinical workflows, ultimately aiming to improve patient outcomes through more accurate, data-driven prognostic planning.
See full Interpace Biosciences company page
